Tag: opioid guidelines

  • Patients On Opioids May Have A Harder Time Finding Primary Care

    Patients On Opioids May Have A Harder Time Finding Primary Care

    According to a new study, more than 40% of clinics said that they would not take a new patient who was using opioids to manage pain.

    Patients who use prescription opioids to manage their pain may have a harder time accessing primary care, according to a new study. 

    The research, published in the journal JAMA Network Open, found that primary care clinics who were accepting new patients were less likely to take a patient who said that they were using opioids. In fact, more than 40% of clinics said that they would not take a new patient who was using opioids to manage pain. 

    Finding Care

    “These findings are concerning because it demonstrates just how difficult it may be for a patient with chronic pain searching for a primary care physician,” lead study author Pooja Lagisetty told the blog of the University of Michigan. 

    For the study, researchers cold-called clinics that were accepting new patients. The callers said they were looking for a new provider for their parent, who took a Percocet (oxycodone) each day to manage pain. 

    The findings confirmed the researchers’ hypothesis that people on opioids have a harder time accessing primary care. Forty percent of the clinics said they would not take the patient, while two-thirds said they would require a preliminary visit before deciding. Seventeen percent said they would need additional information to make a decision. 

    Pain Refugees

    “Anecdotally, we were hearing about patients with chronic pain becoming ‘pain refugees,’ being abruptly tapered from their opioids or having their current physician stop refilling their prescription, leaving them to search for pain relief elsewhere,” Lagisetty said. “However, there have been no studies to quantify the extent of the problem.”

    Surprisingly, the researchers found that whether a patient had private insurance or Medicare did not make a difference in whether or not they were accepted as a new patient. 

    “Our results did not differ by insurance status, which was surprising because previous studies on primary care access have showed that patients on Medicaid tend to have lower access to primary care than those with private insurance,” Lagisetty said. “This may indicate that providers and clinics are not making these decisions to restrict access based upon reimbursement. Larger clinics and community health centers were more likely to accept new patients suggesting that there may be some system level factors that affect access to care.”

    The lack of access to primary care is especially concerning in this case because the researchers who called clinics said that the patient was also on medication for high blood pressure and high cholesterol, both of which require regular treatment from a provider.

    In addition, having a primary care provider can help people manage their use of opioids and taper off them, if possible. 

    “We hope to use this information to identify a way for us to fix the policies to have more of a patient-centered approach to pain management,” Lagisetty said. “Everyone deserves equitable access to health care, irrespective of their medical conditions or what medications they may be taking.”

    View the original article at thefix.com

  • FDA Considers Limiting Outpatient Opioid Prescriptions

    FDA Considers Limiting Outpatient Opioid Prescriptions

    The FDA is taking feedback from the public as it weighs the decision to reduce high-dose prescription painkillers delivered in outpatient settings. 

    Advisors for the Food and Drug Administration (FDA) met last week to discuss a possible cap on high-dose opioids delivered in an outpatient setting, a move that is intended to reduce the risk of addiction and dependency. 

    According to MedPage Today, the meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesia Drug Products Advisory Committee included presentations by doctors, and discussions by policymakers. 

    In a memorandum released ahead of the meeting, advisors for the FDA said that the conference aims to address dual concerns. 

    “When considering regulatory strategies relating to opioid analgesics, FDA always considers two fundamental public health goals: 1. We want to reduce opioid misuse, abuse, addiction, overdoses and deaths. 2. We want to ensure that products are available to meet the medical needs of people living with debilitating pain,” the memo read. 

    “We are also interested in discussing the magnitude and frequency of harms associated with higher doses of opioid analgesics relative to lower doses, as well as optimal strategies for managing these risks while ensuring access to appropriate pain management for patients,” Judy Staffa, associate director for the Public Health Initiatives Office of Surveillance and Epidemiology at the Center for Drug Evaluation and Research (CDER), wrote in the memorandum that was sent to conference attendees. 

    Restricting highly addictive high-dose opioids while also meeting the needs of patients with chronic pain has been a delicate balancing act that many people feel has not been addressed well by federal regulators. The meeting last week was an attempt to continue discussions about how best to serve both needs. 

    “There is a strong need to bring together the community of stakeholders to consider the collective scientific understanding of the issues relating to higher daily doses and higher dosage strength opioid analgesic products and potential strategies to reduce risks to patient and public health,” Staffa wrote. 

    Dr. Ning Hu, medical officer of the CDER’s Division of Anesthesia, Analgesia, and Addiction Products, said that high-dose opioids are dangerous, but so is uncontrolled pain, which—in the most severe cases—can cause people to consider suicide.

    Many prescribers followed the CDC’s 2016 guidelines for prescribing opioids, but those were interpreted too drastically, Hu wrote. 

    “The guidelines were misinterpreted and misapplied, contributing to substantial harms to patients, particularly patients with chronic pain who were forced to taper their previously stable opioid doses to lower doses, or who were forced to discontinue their opioids through forced tapers or patient abandonment,” Hu wrote. 

    In addition to the discussions happening at the conference, the FDA has opened public comment on the issue of high-dose opioids. Public comment will remain open through June 30, and is available here

    View the original article at thefix.com